Peptide Research
GLP-1 Receptor Agonists and Liver Disease: What the MASH Trials Show
⚠ FOR EDUCATIONAL AND SCIENTIFIC REFERENCE PURPOSES ONLY. THIS ARTICLE SUMMARISES PUBLISHED CLINICAL LITERATURE AND IS NOT MEDICAL ADVICE.
Quick answer: The phase 3 ESSENCE trial, published in the New England Journal of Medicine, reported that once-weekly semaglutide 2.4 mg produced resolution of steatohepatitis without worsening fibrosis in 62.9% of participants versus 34.3% on placebo at 72 weeks, alongside significant fibrosis improvement. On that interim evidence, the FDA granted accelerated approval in August 2025 for MASH with moderate-to-advanced fibrosis (stages F2–F3), excluding cirrhosis. Confirmatory outcome data from part 2 of the trial is expected in 2029.
From NAFLD to MASLD: Why the Terminology Changed
What was previously called non-alcoholic fatty liver disease (NAFLD) is now termed metabolic dysfunction-associated steatotic liver disease (MASLD), with its inflammatory form designated metabolic dysfunction-associated steatohepatitis (MASH). The renaming reflects a shift in scientific framing — defining the condition by its metabolic drivers rather than by the absence of alcohol.
The scale explains the research interest. Published estimates suggest approximately one in twenty US adults lives with MASH, and roughly one in three individuals with overweight or obesity. Left untreated, MASH can progress to cirrhosis, hepatocellular carcinoma, and liver transplantation.
ESSENCE: Trial Design
ESSENCE (NCT04822181) is an ongoing international, multicentre, double-blind, placebo-controlled phase 3 randomised trial:
- Population: 1,197 participants with biopsy-confirmed MASH and fibrosis stage F2 or F3 (NASH CRN classification)
- Randomisation: 2:1 to subcutaneous semaglutide 2.4 mg weekly or placebo, in addition to standard care
- Duration: 240 weeks total, structured in two parts — part 1 assessing histological endpoints, part 2 assessing clinical outcomes
- Interim analysis: prespecified at week 72 among the first 800 randomised participants
Notably, biopsy confirmation at entry and histological endpoints at follow-up distinguish this trial design from studies relying on imaging or serum markers alone.
Reported Interim Outcomes at 72 Weeks
| Endpoint | Semaglutide (n=534) | Placebo (n=266) |
|---|---|---|
| Resolution of steatohepatitis without worsening fibrosis | 62.9% | 34.3% |
| Fibrosis improvement (≥1 stage) without worsening steatohepatitis | Approximately 37% | Approximately 22% |
| Mean body weight reduction | 10–11% | Minimal |
The estimated difference for the first primary endpoint was 28.7 percentage points (95% CI, 21.1 to 36.2; P<0.001). Investigators noted that this trial demonstrated improvement in both steatohepatitis activity and fibrosis stage — a distinction from the earlier phase 2 study, which showed MASH resolution alone. The fibrosis result carries particular weight because fibrosis stage is the histological feature most strongly associated with liver-related outcomes.
Regarding hepatic safety, published reports noted no discontinuations attributable to liver enzyme elevations. The most common adverse events were gastrointestinal — nausea, diarrhoea, constipation, vomiting — generally mild and transient.
Weight-Dependent and Weight-Independent Mechanisms
An open mechanistic question runs through this literature: how much of the hepatic benefit follows from weight reduction, and how much reflects direct effects on liver tissue?
Published pharmacological reviews report that semaglutide modulates lipid metabolism and attenuates hepatic inflammation through pathways that appear at least partly independent of weight loss, including downregulation of certain lipogenic pathways. Trial commentators similarly observed that the intervention appears to address underlying metabolic dysfunction driving disease progression, not hepatic pathology alone. However, the relative contribution of each mechanism has not been quantified.
Regulatory and Guideline Context
- August 2025: FDA granted accelerated approval to semaglutide 2.4 mg (Wegovy) for MASH with moderate-to-advanced fibrosis, excluding cirrhosis — the first GLP-1 receptor agonist approved for this indication.
- Prior approval: resmetirom, a thyroid hormone receptor-beta agonist, received approval in March 2024 for the same population, making semaglutide the second approved therapy.
- November 2025: AASLD updated its MASLD practice guidance to incorporate semaglutide as a therapeutic option for adults with MASH and F2–F3 fibrosis.
- Under investigation: tirzepatide has been evaluated in the SYNERGY-NASH programme, with additional dual and triple agonists in earlier-stage hepatic research.
What Remains Unestablished
- Clinical outcomes are pending. Accelerated approval rested on histological surrogates. Part 2 of ESSENCE, reporting death, transplantation, and liver-related events, is expected in 2029.
- Cirrhosis is excluded. The approved indication and trial population exclude compensated cirrhosis, so evidence in advanced disease is absent.
- Durability is uncharacterised. Whether histological improvement persists after discontinuation has not been studied — relevant given the broader discontinuation literature.
- Combination strategies are untested. Commentators identify rational combination therapy as the next research frontier, but supporting trial data does not yet exist.
Regulatory Status
The compounds discussed in this article — semaglutide, tirzepatide, and related receptor agonists — exist as FDA-approved prescription pharmaceutical products, prescribed and monitored by licensed clinicians. This article summarises published clinical literature about those approved products for scientific reference only.
LiveWell Peptides supplies research-grade compounds strictly for in-vitro laboratory research. Research materials are not pharmaceutical products, are not manufactured or approved for clinical use, are not substitutes for any prescription medication, and are not intended for human or animal administration. No comparison to any approved pharmaceutical product is made or implied, and nothing here constitutes guidance about any individual’s medical care.
Frequently Asked Questions
What is MASH, and how does it differ from MASLD?
MASLD (metabolic dysfunction-associated steatotic liver disease) describes fat accumulation in the liver linked to metabolic dysfunction. MASH is its inflammatory form, involving hepatocyte injury and often fibrosis. Both terms replaced the older NAFLD and NASH nomenclature.
What did the ESSENCE trial report?
At the prespecified 72-week interim analysis, 62.9% of semaglutide-treated participants achieved resolution of steatohepatitis without worsening fibrosis versus 34.3% on placebo, with approximately 37% versus 22% achieving fibrosis improvement without worsening steatohepatitis.
Is the liver benefit purely a result of weight loss?
Not entirely, according to published pharmacological reviews, which report modulation of lipid metabolism and attenuation of hepatic inflammation through partly weight-independent pathways. The relative contribution of each mechanism has not been quantified.
Does the approval cover cirrhosis?
No. The approved indication covers MASH with moderate-to-advanced fibrosis (stages F2–F3) and excludes cirrhosis. The trial population was defined the same way, so evidence in advanced disease is not available.
Why is fibrosis improvement considered significant?
Fibrosis stage is the histological feature most strongly associated with liver-related outcomes including cirrhosis and liver-related mortality. The phase 2 study showed MASH resolution alone; the phase 3 trial reported improvement in both activity and fibrosis stage.
When will confirmatory outcome data be available?
Part 2 of ESSENCE extends to 240 weeks and evaluates clinical outcomes including death, liver transplantation, and liver-related events. Results are expected in 2029, which is the basis on which accelerated approval will be confirmed or reconsidered.
Related Research
Continue reading: GLP-1 and Sleep Apnea: SURMOUNT-OSA Findings · GLP-1 Discontinuation and Weight Regain · Mitochondrial Peptides in Research
External context: ESSENCE on ClinicalTrials.gov · PubMed
References
- Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089–2099.
- Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2025.
- U.S. Food and Drug Administration. Accelerated approval of semaglutide 2.4 mg for MASH with moderate-to-advanced fibrosis. August 2025.
- Semaglutide in MASH with F2–F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial. Metab Target Organ Damage. 2026;13.
- Nowak K, et al. Therapeutic potential of GLP-1 receptor agonists in metabolic associated steatotic liver disease. Ann Pharmacother. 2025;59(10):928–936.
- American College of Gastroenterology. Semaglutide for the treatment of metabolic dysfunction-associated steatohepatitis. EBGI. 2025.
- ClinicalTrials.gov. ESSENCE trial, NCT04822181.
Educational reference only. This article summarises findings from published clinical literature as a scientific reference. It is not medical advice, contains no dosing or treatment guidance, and should not be used to make healthcare decisions. Individuals with questions about liver disease or prescribed medications should consult a licensed clinician. LiveWell Peptides products are supplied strictly for in-vitro laboratory research, are not pharmaceutical products, and are not for human or animal consumption.